Targets › POLRMT
1 program from 1 company in 10 trials: 7 Phase 4, 2 Phase 2, 1 Phase 3; Infectious disease; next expected readout Mar 2027.
DNA-dependent RNA polymerase catalyzes the transcription of mitochondrial DNA into RNA using the four ribonucleoside triphosphates as substrates. Component of the mitochondrial transcription initiation complex, composed at least of TFB2M, TFAM and POLRMT that is required for basal transcription of mitochondrial DNA. In this complex, TFAM recruits POLRMT to a specific promoter whereas TFB2M induces structural changes…. (UniProt, O00411)
Open in Phaseline: the race on POLRMT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gilead Sciences | Tenofovir Alafenamide Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLRMT, RT | Phase 2 | Acquired Immune Deficiency Syndrome (AIDS); Chronic Hepatitis B; Hepatitis B Reactivation; Chronic Hepatitis b … | Mar 2027 |
Chronic Hepatitis b (3) Hepatitis B (2) Acquired Immune Deficiency Syndrome (AIDS) (1) Chronic Hepatitis B (1) Hepatitis B Reactivation (1) Hepatitis B, Chronic (1) Safety Issues (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.